**Question:** Drug used in unstable angina & NSTEMI

**Core Concept:** Unstable angina and Non-ST segment elevation myocardial infarction (NSTEMI) are clinical conditions characterized by acute coronary artery occlusion leading to chest pain and myocardial ischemia. These conditions require prompt medical intervention, including antiplatelet therapy, vasodilators, and beta-blockers.

**Why the Correct Answer is Right:** The correct answer is D, Anthrombocthera. Anthrombocthera is a combination of two drugs:

1. **Anthrolytic:** This refers to the antiplatelet agent clopidogrel, which inhibits platelet aggregation and prevents further platelet activation, thereby reducing the risk of further thrombotic events in unstable angina and NSTEMI patients.
2. **Thrombolytic:** This refers to the thrombolytic agent, ticagrelor, which is a potent platelet inhibitor like clopidogrel but with a shorter half-life. It works to reduce platelet aggregation and prevents the formation of a new platelet plug.

**Why Each Wrong Option is Incorrect:**

A. Morphine (Option A): Morphine is an opioid analgesic primarily used for pain relief and sedation. It does not address the underlying pathophysiology of unstable angina and NSTEMI, and might even worsen the condition by causing hypotension or respiratory depression.

B. Aspirin (Option B): Aspirin is a non-selective COX inhibitor that reduces platelet aggregation; however, its use in unstable angina and NSTEMI is limited due to its irreversible nature, which may lead to bleeding complications. Additionally, it is less effective than clopidogrel in preventing further thrombotic events.

C. Nitrates (Option C): Nitrates are vasodilators that relieve angina symptoms by dilating coronary arteries, but they do not address the underlying pathophysiology of unstable angina and NSTEMI, and are generally not preferred due to their short duration of action and potential for tolerance development.

D. Anthrombocthera (Option D): As explained above, Anthrombocthera combines the benefits of clopidogrel (as an antiplatelet agent) and ticagrelor (a potent antiplatelet agent with a shorter half-life than clopidogrel) to address the pathophysiology of unstable angina and NSTEMI effectively.

E. Calcium Channel Blockers (Option E): Calcium channel blockers are used for angina management and hypertension but do not directly address the thrombotic events in unstable angina and NSTEMI. They may even worsen the condition by causing myocardial ischemia.

**Core Concept:** Unstable angina and NSTEMI are conditions requiring rapid intervention to prevent further thrombotic events and reduce myocardial infarction risk. Anthrombocthera offers a combination of antiplatelet agents with complementary mechanisms of action to address the pathophysiology of unstable angina and NSTEMI effectively.